323 related articles for article (PubMed ID: 26227551)
1. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.
Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP
Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551
[TBL] [Abstract][Full Text] [Related]
2. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
[TBL] [Abstract][Full Text] [Related]
4. Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors.
Righetti G; Casale M; Liessi N; Tasso B; Salis A; Tonelli M; Millo E; Pedemonte N; Fossa P; Cichero E
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138251
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel F508del-CFTR traffic correctors among triazole derivatives.
Bacalhau M; Ferreira FC; Kmit A; Souza FR; da Silva VD; Pimentel AS; Amaral MD; Buarque CD; Lopes-Pacheco M
Eur J Pharmacol; 2023 Jan; 938():175396. PubMed ID: 36410419
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays.
Parodi A; Righetti G; Pesce E; Salis A; Tasso B; Urbinati C; Tomati V; Damonte G; Rusnati M; Pedemonte N; Cichero E; Millo E
Eur J Med Chem; 2020 Dec; 208():112833. PubMed ID: 32971410
[TBL] [Abstract][Full Text] [Related]
7. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
Laselva O; Molinski S; Casavola V; Bear CE
Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011
[TBL] [Abstract][Full Text] [Related]
8. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools.
Liessi N; Cichero E; Pesce E; Arkel M; Salis A; Tomati V; Paccagnella M; Damonte G; Tasso B; Galietta LJV; Pedemonte N; Fossa P; Millo E
Eur J Med Chem; 2018 Jan; 144():179-200. PubMed ID: 29272749
[TBL] [Abstract][Full Text] [Related]
10. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
11. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
[TBL] [Abstract][Full Text] [Related]
12. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
13. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.
Van Goor F; Hadida S; Grootenhuis PD; Burton B; Stack JH; Straley KS; Decker CJ; Miller M; McCartney J; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu PA
Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18843-8. PubMed ID: 21976485
[TBL] [Abstract][Full Text] [Related]
14. Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel.
Renda M; Barreca M; Borrelli A; Spanò V; Montalbano A; Raimondi MV; Bivacqua R; Musante I; Scudieri P; Guidone D; Buccirossi M; Genovese M; Venturini A; Bandiera T; Barraja P; Galietta LJV
Sci Rep; 2023 May; 13(1):7604. PubMed ID: 37165082
[TBL] [Abstract][Full Text] [Related]
15. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
[TBL] [Abstract][Full Text] [Related]
16. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.
Farinha CM; King-Underwood J; Sousa M; Correia AR; Henriques BJ; Roxo-Rosa M; Da Paula AC; Williams J; Hirst S; Gomes CM; Amaral MD
Chem Biol; 2013 Jul; 20(7):943-55. PubMed ID: 23890012
[TBL] [Abstract][Full Text] [Related]
17. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface.
Eckford PD; Ramjeesingh M; Molinski S; Pasyk S; Dekkers JF; Li C; Ahmadi S; Ip W; Chung TE; Du K; Yeger H; Beekman J; Gonska T; Bear CE
Chem Biol; 2014 May; 21(5):666-78. PubMed ID: 24726831
[TBL] [Abstract][Full Text] [Related]
18. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
[TBL] [Abstract][Full Text] [Related]
19. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing.
Boinot C; Jollivet Souchet M; Ferru-Clément R; Becq F
J Pharmacol Exp Ther; 2014 Sep; 350(3):624-34. PubMed ID: 24970923
[TBL] [Abstract][Full Text] [Related]
20. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
